Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer.

Kim, Boyeon; Kim, Yoonjung; Shin, Saeam; Lee, Seung-Tae; Cho, Jae Yong; Lee, Kyung-A

Kim, Boyeon; Kim, Yoonjung; Shin, Saeam; Lee, Seung-Tae; Cho, Jae Yong; Lee, Kyung-A.

Afiliación

Kim B; Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-Ro, Gangnam-Gu, Seoul, 06273, Republic of Korea.
Kim Y; Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-Ro, Gangnam-Gu, Seoul, 06273, Republic of Korea.
Shin S; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Lee ST; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Cho JY; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 06273, Republic of Korea.
Lee KA; Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-Ro, Gangnam-Gu, Seoul, 06273, Republic of Korea. kal1119@yuhs.ac.

Cancer Cell Int ; 22(1): 82, 2022 Feb 15.

Article en En | MEDLINE | ID: mdl-35168603

Palabras clave

CRISPR-Cas System; Cell-free nucleic acids; EGFR gene; Liquid biopsy; Non-small cell lung cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Guideline Idioma: En Revista: Cancer Cell Int Año: 2022 Tipo del documento: Article